Peptide questions · ARA-290

How long does ARA-290 take to work?

Reviewed Evidence: ModeratePublished by PepVault

ARA-290’s onset is 1–2 weeks (user reports; the trials' main readouts were at day 28), its peak effect comes at 4 weeks, the point the trials measured, and its typical duration is 4 weeks, often repeated, by the library’s timeline (backed by moderate evidence).

The timeline’s basis: Four small randomized phase 2 trials (about 200 people in all), each run or co-authored by its developer, plus rat nerve-injury work. No approval anywhere.

ARA-290 week by week

The library places four of its research notes on ARA-290 on the days they cover, from day 1 to day 120: 1 on community reports, 2 on randomized trials and 1 on clinical data.

Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.

The ARA-290 notes by day
WhenThe noteEvidence
Days 1–14 (weeks 1–2)The first two weeks: for some, the burning easesCommunity report
Days 14–28 (weeks 2–4)Four weeks is where the trials lookedRandomized trial
Days 28–56 (weeks 4–8)What happened after the dosing stoppedRandomized trial
Days 56–120 (weeks 8–18)Past the trials' windowClinical data
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track ARA-290 in PepVault

Log each dose and your weekly check-ins, and see your own weeks add up.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The ARA-290 timeline’s milestones

The library’s timeline for ARA-290 marks 8 points from week 1 to week 16, backed by moderate evidence overall.

  • Week 1: Commonly reported: burning or tingling starting to settle inside the first one to two weeks, though plenty of people notice nothing yet
  • Week 2: Works by switching on the innate repair receptor; in rats, that damped the spinal inflammation behind nerve pain for weeks after dosing stopped
  • Week 3: In one trial the gap in how much pain interfered with daily life opened by the third week of dosing
  • Week 4: In a sarcoidosis trial, nerve-symptom scores improved more than placebo after 28 daily doses, and the corneal nerve-fiber measure rose
  • Week 5: A week after the last dose the improvement was still there in that sarcoidosis trial; pain intensity itself improved equally on placebo
  • Week 8: In the diabetes trial the gap over placebo was wider four weeks after dosing ended than on the last day of it
  • Week 12: Trial follow-up found the symptom gain holding about 12 weeks after the last dose, with no more drug given
  • Week 16: Community runs commonly stop at four weeks and are repeated later; past 12 weeks of dosing there is no published data

The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.

Why ARA-290 takes that long

ARA-290’s half-life is about 20 minutes, so one dose is about 96.9% cleared after 1.7 hours.

Each dose of ARA-290 clears within 1.7 hours, so its level doesn’t build up from one day to the next: the weeks on the timeline come from repeated doses, not from the compound piling up in the blood.

ARA-290 against other healing & recovery compounds

The library holds an onset-and-peak timeline for 12 healing & recovery compounds, ARA-290 among them; none of the others shares its onset of 1–2 weeks (user reports; the trials' main readouts were at day 28).

When healing & recovery compounds start to act and peak, by the library’s timelines
CompoundOnsetPeak effect
BPC-1571–7 days2–4 weeks
TB-5001–2 weeks4–6 weeks
GHK-Cu3–6 weeks8–12 weeks
KPV1–2 weeks4–6 weeks
ThymalinNot established (no controlled timing data)Not established
ThymogenNot established (no controlled timing data)Not established
VilonNot established (no controlled timing data)Not established
LinaclotideWeek 1 (bowel movements)1–12 weeks
ARA-2901–2 weeks (user reports; the trials' main readouts were at day 28)4 weeks, the point the trials measured
CartalaxDays to weeks (commonly reported)Weeks (commonly reported)
Teriparatide1–3 months (bone formation markers, spine BMD)18–24 months (BMD, fracture risk)
Abaloparatide1 month (bone formation markers)12–18 months (BMD, fracture risk)

Questions people ask

How long does ARA-290 take to work?

ARA-290’s onset is 1–2 weeks (user reports; the trials' main readouts were at day 28), its peak effect comes at 4 weeks, the point the trials measured, and its typical duration is 4 weeks, often repeated, by the library’s timeline (backed by moderate evidence).

When does ARA-290 reach its peak effect?

By the library’s timeline, ARA-290’s peak effect comes at 4 weeks, the point the trials measured, backed by moderate evidence.

How long is ARA-290 usually run?

The library’s timeline gives ARA-290’s typical duration as 4 weeks, often repeated; its cycle note says: The published daily courses ran 28 days (three trials) and 12 weeks (the eye study).

What does the library say about the first days on ARA-290?

Its first note on ARA-290, for days 1–14 (weeks 1–2), is “The first two weeks: for some, the burning eases”, resting on community reports.

More on ARA-290

Track it in the app

PepVault for iPhone

Track ARA-290 in PepVault

Log each dose and your weekly check-ins, and see your own weeks add up.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo